Gilead Sciences

Healthcare

Gilead Strikes $7.8 Billion Deal for Control of Cancer Biotech Arcellx

Photo via Yichuan Cao/Sipa USA/Newscom

The pharma giant already held an 11.5% stake as part of a 2022 effort to co-develop and co-commercialize the cancer treatment anito-cel.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.